Since the core of our mission  was to develop the health quality level in the country, in April of 2015 we started to provide New Direct Acting HCV treatment, manufactured by our partner Mylan Pharmaceuticals, under license from Gilead Sciences Inc., at very reasonable prices.

We launched a campaign to make patients aware of the curability of Hepatitis C. Many patients were then referred to doctors in various public hospitals, and by the end of 2016, more than 390 patients were successfully cured with the help of our products without any relapse.